You can relax in a comfortable setting designed to minimize any anxiety
Your drug regimen may be adjusted over time, possibly to include a third drug and/or insulin, depending on how you respond to initial therapy
The GLP-1 Bridge Program is scheduled to begin on July 1, 2026, and is currently authorized to run through December 31, 2027
Over time, these simple chats allow Jurni GLP to recognize your unique patterns, transforming the chore of tracking into a deep understanding of your journey
For instance, in September 2025, Novo Nordisk announced that the Phase 3 OASIS 4 trial demonstrated once-daily oral semaglutide 25 mg produced significantly greater weight loss than placebo in adults with overweight or obesity, supporting the advancement of next-generation oral GLP-1 therapies as a convenient alternative to injectable treatments
The earlier we act, the more we can truly protect the liver